静脉氯胺酮输注用于急性疼痛管理的共识指南
该共识指南由美国区域麻醉与疼痛医学学会、美国疼痛医学学会和美国麻醉医师学会共同制定,针对急性疼痛中静脉氯胺酮输注的适应证、禁忌证、作为阿片类药物辅助治疗的证据、患者自控氯胺酮镇痛、非肠道剂型及亚麻醉剂量范围达成共识,并指出需要更大规模研究优化患者选择和治疗参数。
要点
- 证据支持氯胺酮用于多种情况下的急性疼痛,包括作为独立治疗、作为阿片类药物辅助治疗以及较少程度的鼻内制剂。
- 急性疼痛的禁忌证与慢性疼痛相似,部分基于剂量范围相似的观察。
- 需要更大规模研究评估不同急性疼痛状况,以优化患者选择、确定非肠道氯胺酮替代品的有效性、定义最佳治疗参数并制定方案。
核心结论
- 证据支持氯胺酮用于多种情况下的急性疼痛,包括作为独立治疗、作为阿片类药物辅助治疗以及较少程度的鼻内制剂。
- 急性疼痛的禁忌证与慢性疼痛相似,部分基于剂量范围相似的观察。
- 需要更大规模研究评估不同急性疼痛状况,以优化患者选择、确定非肠道氯胺酮替代品的有效性、定义最佳治疗参数并制定方案。
研究设计与样本
- 该共识指南由美国区域麻醉与疼痛医学学会和美国疼痛医学学会董事会委托制定,并由美国麻醉医师学会疼痛医学委员会及标准与实践参数委员会批准。
- 委员会主席根据电话会议中委员会的输入提出问题,由3至5名小组委员会成员和委员会主席负责回答个别问题,初步共识达成后全体委员会通过电子邮件和电话会议进一步修订。
主要发现
- 共识指南涉及以下领域:适应证、急性疼痛的禁忌证及其与慢性疼痛禁忌证的区别、氯胺酮作为阿片类药物辅助治疗的证据、支持患者自控氯胺酮镇痛的证据、非肠道剂型氯胺酮的使用以及亚麻醉剂量范围及证据是否支持这些剂量用于急性疼痛。
- 小组能够就所有问题的答案达成共识。
临床怎么用
- 证据支持氯胺酮用于多种情况下的急性疼痛,包括作为独立治疗、作为阿片类药物辅助治疗以及较少程度的鼻内制剂。
- 急性疼痛的禁忌证与慢性疼痛相似,部分基于剂量范围相似的观察。
局限性
- 需要更大规模研究评估不同急性疼痛状况,以优化患者选择、确定非肠道氯胺酮替代品的有效性、定义最佳治疗参数并制定方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Ketamine infusions have been used for decades to treat acute pain, but a recent surge in usage has made the infusions a mainstay of treatment in emergency departments, in the perioperative period in individuals with refractory pain, and in opioid-tolerant patients. The widespread variability in patient selection, treatment parameters, and monitoring indicates a need for the creation of consensus guidelines. METHODS: The development of acute pain ketamine guidelines grew as a corollary from the genesis of chronic pain ketamine guidelines. The charge for the development of acute pain ketamine guidelines was provided by the Boards of Directors of both the American Society of Regional Anesthesia and Pain Medicine and the American Academy of Pain Medicine, who approved the document along with the American Society of Anesthesiologists' Committees on Pain Medicine and Standards and Practice Parameters. The committee chair developed questions based on input from the committee during conference calls, which the committee then refined. Groups of 3 to 5 panel members and the committee chair were responsible for answering individual questions. After preliminary consensus was achieved, the entire committee made further revisions via e-mail and conference calls. RESULTS: Consensus guidelines were prepared in the following areas: indications, contraindications for acute pain and whether they differ from those for chronic pain, the evidence for the use of ketamine as an adjunct to opioid-based therapy, the evidence supporting patient-controlled ketamine analgesia, the use of nonparenteral forms of ketamine, and the subanesthetic dosage range and whether the evidence supports those dosages for acute pain. The group was able to reach consensus on the answers to all questions. CONCLUSIONS: Evidence supports the use of ketamine for acute pain in a variety of contexts, including as a stand-alone treatment, as an adjunct to opioids, and, to a lesser extent, as an intranasal formulation. Contraindications for acute pain are similar to those for chronic pain, partly based on the observation that the dosage ranges are similar. Larger studies evaluating different acute pain conditions are needed to enhance patient selection, determine the effectiveness of nonparenteral ketamine alternatives, define optimal treatment parameters, and develop protocols optimizing safety and access to care.
引用
- Schwenk ES, Viscusi ER, Buvanendran A, et al. Consensus Guidelines on the Use of Intravenous Ketamine Infusions for Acute Pain Management From the American Society of Regional Anesthesia and Pain Medicine, the American Academy of Pain Medicine, and the American Society of Anesthesiologists. Reg Anesth Pain Med. 2018. PMID: 29870457. doi:10.1097/AAP.0000000000000806
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。